ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Aldeyra Therapeutics, Inc. (ALDX)
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aldeyra.com/investor-relations
Company Research
Source: Business Wire
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or “the Company”) (NASDAQ: ALDX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Aldeyra announced on April 3, 2025, that the FDA had issued a Complete Response Letter based on its NDA for reproxalap. The FDA letter stated that the Company’s NDA “failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes.” Despite the Company’s claims that its clinical trial data was “uniquely supportive” of the drug’s positive results, the FDA stated it has concerns about the trial data it supported as part of the NDA. Based on this news, shares of Aldeyra fell by almost 75% over the course o
Show less
Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDX alerts
High impacting Aldeyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALDX
News
- Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript [Seeking Alpha]Seeking Alpha
- Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease [Yahoo! Finance]Yahoo! Finance
- Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye DiseaseBusiness Wire
- Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript [Seeking Alpha]Seeking Alpha
- Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast [Yahoo! Finance]Yahoo! Finance
ALDX
Earnings
- 11/5/25 - Beat
ALDX
Sec Filings
- 12/16/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- 11/13/25 - Form 8-K
- ALDX's page on the SEC website